Adverse drug reactions to apomorphine: a worldwide pharmacovigilancedatabase analysis
Objective: To determine the safety profile of apomorphine (expected vs. new signals), regardless of the indication and route of administration. Background: Adverse drug reactions (ADR)…Impact of device-aided therapies on QoL and Off-time improvement in advanced Parkinson’s Disease patients: Comparative effectiveness results from a Bayesian Network Meta-Analysis
Objective: To compare off-time and QoL changes among APD patients taking LCIG, DBS, CSAI, and BMT at 6 months after therapy initiation. Background: Advanced Parkinson’s…Deterioration in oral health status potentially associated with apomorphine pump initiation: a case report
Objective: To describe the case of a patient with Parkinson’s disease (PD) who suffered from a rapid deterioration of his oral health status following treatment…Apomorphine infusion before subthalamic deep brain stimulation. A prospective comparative study in the same 20 patients.
Objective: The objetive of this study was to compare the benefit of APO and STN-DBS in aPD in terms of motor (off daily hours, UPDRS…Indirect Comparison of Apomorphine Sublingual Film Versus Levodopa Inhalation Powder for “OFF” Episodes in Parkinson’s Disease
Objective: Conduct a matching-adjusted indirect comparison (MAIC) of the efficacy of apomorphine sublingual film (APL) vs levodopa inhalation powder (CVT-301) for “OFF” episodes in Parkinson’s…Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Europe vs North America
Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD)…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Characterization of Acute Nausea During Dose Titration
Objective: Characterize acute episodes of nausea experienced by patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for the on-demand treatment of “OFF” episodes.…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Analysis of Baseline Factors
Objective: Determine if baseline factors are associated with the apomorphine sublingual film (APL) dose required to achieve FULL “ON.” Background: APL is approved for the…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Dyskinesia
Objective: Assess impact of apomorphine sublingual film (APL) on time spent with and functional impact of dyskinesia among patients with Parkinson’s disease (PD) and “OFF”…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact of Concomitant Antiemetics on Nausea and Vomiting
Objective: Analyze the effect of concomitant trimethobenzamide (TMB) on nausea and vomiting rates in patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 11
- Next Page »